Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol

Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol

Introduction Non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a phenotype of the metabolic syndrome in the liver and is clearly associated with metabolic abnormalities such as hyperglycaemia and dyslipidaemia. Although the prevalenc...

Full description

Saved in:
Bibliographic Details
Main Authors: Takaaki Sugihara, Atsushi Nakajima, Hirokazu Takahashi, Satoshi Koyama, Atsushi Kawaguchi, Kento Imajo, Masato Yoneda, Yuji Ogawa, Takashi Kobayashi, Asako Nogami, Takeo Kurihashi, Shuichi Sato, Nobuharu Tamaki, Yuki Yamaguchi, Michihiro Iwaki, Eiji Sakai, Ryuta Shigefuku, Yoshinobu Nakada, Noriko Oza, Toshikazu Kohira, Michiaki Okada, Shinji Iwane, Fujito Kageyama, Yuzo Sasada, Masahiro Matsushita, Akimitsu Tadauchi, Gou Murohisa, Masamichi Nagasawa, Kazuhisa Maeda, Koichiro Furuta, Yuya Seko, Hiroshi Tobita, Kazuhito Kawata, Miwa Kawanaka, Motoh Iwasa, Takumi Kawaguchi, Yoshito Itoh
Format: Article
Language:English
Published: BMJ Publishing Group 2024-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/11/e088862.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/14/11/e088862.full

Similar Items